Bellevue Group AG Has $75.51 Million Stake in Evolent Health, Inc. (NYSE:EVH)

Bellevue Group AG increased its stake in Evolent Health, Inc. (NYSE:EVH - Free Report) by 59.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,670,050 shares of the technology company's stock after purchasing an additional 1,000,215 shares during the quarter. Evolent Health makes up 1.2% of Bellevue Group AG's investment portfolio, making the stock its 24th largest holding. Bellevue Group AG owned about 2.30% of Evolent Health worth $75,509,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Covestor Ltd raised its holdings in shares of Evolent Health by 138.1% during the third quarter. Covestor Ltd now owns 1,424 shares of the technology company's stock worth $40,000 after acquiring an additional 826 shares in the last quarter. GAMMA Investing LLC increased its position in Evolent Health by 5,365.5% in the 3rd quarter. GAMMA Investing LLC now owns 1,585 shares of the technology company's stock worth $45,000 after purchasing an additional 1,556 shares during the last quarter. Quarry LP purchased a new stake in shares of Evolent Health during the 2nd quarter worth about $32,000. Canada Pension Plan Investment Board acquired a new stake in shares of Evolent Health during the 2nd quarter valued at about $61,000. Finally, Quest Partners LLC bought a new stake in shares of Evolent Health in the 2nd quarter valued at approximately $87,000.

Evolent Health Stock Performance

Shares of EVH traded down $0.01 during mid-day trading on Friday, hitting $12.92. The company's stock had a trading volume of 1,102,713 shares, compared to its average volume of 3,654,132. Evolent Health, Inc. has a one year low of $11.17 and a one year high of $35.00. The stock's 50-day moving average is $21.47 and its two-hundred day moving average is $23.33. The firm has a market capitalization of $1.51 billion, a PE ratio of -14.20 and a beta of 1.58. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.04 and a current ratio of 1.04.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on EVH. Truist Financial restated a "buy" rating and set a $33.00 price target on shares of Evolent Health in a report on Tuesday, August 27th. Stephens cut Evolent Health from an "overweight" rating to an "equal weight" rating and reduced their price target for the stock from $38.00 to $16.00 in a research report on Friday, November 8th. Oppenheimer lowered their price objective on Evolent Health from $34.00 to $28.00 and set an "outperform" rating on the stock in a report on Monday, November 18th. Citigroup reduced their target price on Evolent Health from $33.00 to $21.00 and set a "buy" rating for the company in a report on Wednesday, November 13th. Finally, Royal Bank of Canada reiterated an "outperform" rating and set a $20.00 price target on shares of Evolent Health in a report on Tuesday, November 12th. One investment analyst has rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $25.90.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.